Atox Bio Raises $3.25 million to Advance Development of AB103, a Novel Therapy for the Treatment of Severe Bacterial Infections, Currently in Phase 2 Clinical Trials

Dec 20, 2011

Atox Bio granted orphan drug designation for AB103 for the treatment of necrotizing soft tissue infections (NSTI)

October 25, 2011

End of Phase 1-Atox Bio announces successful completion of phase 1 for AB103, a novel immunomodulator being developed for severe bacterial infections and sepsis.

May 12, 2011

Atox Bio raises $2.1 Million to advance development of AB103, a novel therapy for the treatment of severe bacterial infections.

October 14, 2010

Atox Bio announces dosing of the first subject in its phase 1 study of AB103. AB103 is a novel immunomodulator being developed for severe bacterial infections and sepsis.

September 14, 2010

Press Releases